73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Insulet Corp
Closed
SectorHealthcare
282.26 1.45
Overview
Share price change
24h
Min
277.33
Max
283.9
Income | 65M 88M |
|---|---|
Sales | 57M 706M |
P/E Sector Avg | 81.21 90.831 |
Profit margin | 12.403 |
Employees | 3,900 |
EBITDA | 90M 160M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +34.66% upside |
Next Earnings | 18 Feb 2026 |
|---|
Market Cap | -2.8B 20B |
|---|---|
Previous open | 280.81 |
Previous close | 282.26 |
News Sentiment
By Acuity
34%
66%
73 / 361 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Insulet Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Insulet Corp Forecast
Price Target
By TipRanks
34.66% upside
12 Months Forecast
Average 374.59 USD 34.66%
High 450 USD
Low 274 USD
Based on 18 Wall Street analysts offering 12 month price targets forInsulet Corp - Dist in the last 3 months.
Sentiment
By Acuity
73 / 361 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Live chat